Jenny E. Blau

2.3k total citations · 1 hit paper
39 papers, 1.5k citations indexed

About

Jenny E. Blau is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Jenny E. Blau has authored 39 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 11 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Surgery. Recurrent topics in Jenny E. Blau's work include Neuroendocrine Tumor Research Advances (14 papers), Neuroblastoma Research and Treatments (7 papers) and Parathyroid Disorders and Treatments (7 papers). Jenny E. Blau is often cited by papers focused on Neuroendocrine Tumor Research Advances (14 papers), Neuroblastoma Research and Treatments (7 papers) and Parathyroid Disorders and Treatments (7 papers). Jenny E. Blau collaborates with scholars based in United States, Sweden and United Kingdom. Jenny E. Blau's co-authors include Kristina I. Rother, Simeon I. Taylor, Michael T. Collins, Sri Harsha Tella, Allison C. Sylvetsky, Mary Walter, Viviana Bauman, Amber L. Beitelshees, Rebecca J. Brown and Peter J. Walter and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Jenny E. Blau

36 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SGLT2 Inhibitors May Predispose to Ketoacidosis

2015 396 citations Simeon I. Taylor, Jenny E. Blau et al. The Journal of Clinical Endocrinology & Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jenny E. Blau United States	15	989	506	478	289	230	39	1.5k
Elena Henkel Germany	16	1.6k 1.6×	347 0.7×	673 1.4×	163 0.6×	43 0.2×	34	2.3k
Hanne L. Gulseth Norway	17	636 0.6×	420 0.8×	354 0.7×	93 0.3×	209 0.9×	31	1.4k
Xiaohan Lu United States	22	530 0.5×	203 0.4×	433 0.9×	50 0.2×	170 0.7×	55	1.3k
Johan Fagerudd Finland	18	670 0.7×	248 0.5×	189 0.4×	255 0.9×	43 0.2×	24	1.5k
Stephen J. Cleland United Kingdom	22	785 0.8×	336 0.7×	318 0.7×	241 0.8×	54 0.2×	37	1.7k
László Bajnok Hungary	18	237 0.2×	278 0.5×	254 0.5×	94 0.3×	54 0.2×	42	989
Angela Doering Germany	17	503 0.5×	101 0.2×	253 0.5×	216 0.7×	118 0.5×	25	1.4k
Brenno Astiarraga Italy	20	1.3k 1.3×	1.1k 2.2×	746 1.6×	124 0.4×	72 0.3×	44	2.4k
Adela Rovira Spain	18	332 0.3×	201 0.4×	341 0.7×	97 0.3×	141 0.6×	53	985
Carsta Koehler Germany	21	1.4k 1.4×	371 0.7×	422 0.9×	184 0.6×	47 0.2×	33	2.1k

Countries citing papers authored by Jenny E. Blau

Since Specialization

Citations

This map shows the geographic impact of Jenny E. Blau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny E. Blau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny E. Blau more than expected).

Fields of papers citing papers by Jenny E. Blau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny E. Blau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny E. Blau. The network helps show where Jenny E. Blau may publish in the future.

Co-authorship network of co-authors of Jenny E. Blau

This figure shows the co-authorship network connecting the top 25 collaborators of Jenny E. Blau. A scholar is included among the top collaborators of Jenny E. Blau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenny E. Blau. Jenny E. Blau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Welch, James, Lynn S. Bliss, Craig Cochran, et al.. (2025). Genotype-phenotype correlation in multiple endocrine neoplasia type 1. JCI Insight. 10(6).

Daniels, Samuel J., Karin Nelander, John Eriksson, et al.. (2025). Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study. Contemporary Clinical Trials Communications. 44. 101437–101437.

Broglio, Kristine, Jenny E. Blau, Elizabeth A. Pilling, & James Wason. (2024). Multidisciplinary considerations for implementing Bayesian borrowing in basket trials. Drug Discovery Today. 29(9). 104127–104127.

Tavaglione, Federica, Paolo Gallo, Antonio De Vincentis, et al.. (2024). Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease. Diabetes/Metabolism Research and Reviews. 40(3). e3787–e3787. 8 indexed citations

Seko, Yuya, Kanji Yamaguchi, Toshihide Shima, et al.. (2023). The greater impact of PNPLA3 polymorphism on liver‐related events in Japanese non‐alcoholic fatty liver disease patients: A multicentre cohort study. Liver International. 43(10). 2210–2219. 21 indexed citations

Blau, Jenny E., Craig Cochran, Sungyoung Auh, et al.. (2021). Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome. The American Journal of Gastroenterology. 116(11). 2216–2221. 3 indexed citations

Blau, Jenny E. & William F. Simonds. (2021). Familial Hyperparathyroidism. Frontiers in Endocrinology. 12. 623667–623667. 19 indexed citations

Suzuki, Mari, Ricardo Correa, Jenny E. Blau, et al.. (2021). Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism. Endocrine. 72(1). 96–103. 9 indexed citations

Hartley, Iris R., Rachel I. Gafni, Kelly L. Roszko, et al.. (2020). Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia. Journal of Bone and Mineral Research. 37(11). 2174–2185. 18 indexed citations

10.

Weinstein, Lee S., et al.. (2020). c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs. Journal of Molecular Endocrinology. 65(2). R1–R17. 5 indexed citations

11.

Taylor, Simeon I., Jenny E. Blau, Kristina I. Rother, & Amber L. Beitelshees. (2019). SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. The Lancet Diabetes & Endocrinology. 7(12). 949–958. 79 indexed citations

12.

Blau, Jenny E., Viviana Bauman, Paolo Piaggi, et al.. (2018). Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight. 3(8). 118 indexed citations

13.

Blau, Jenny E. & Simeon I. Taylor. (2018). Adverse effects of SGLT2 inhibitors on bone health. Nature Reviews Nephrology. 14(8). 473–474. 53 indexed citations

14.

Zagzag, Jonathan, Dhaval Patel, Lee S. Weinstein, et al.. (2018). High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy. Surgery. 165(1). 124–128. 5 indexed citations

15.

Blau, Jenny E., Sri Harsha Tella, Simeon I. Taylor, & Kristina I. Rother. (2017). Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes/Metabolism Research and Reviews. 33(8). 169 indexed citations

16.

Sylvetsky, Allison C., Jenny E. Blau, & Kristina I. Rother. (2016). Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research. Reviews in Endocrine and Metabolic Disorders. 17(2). 187–194. 31 indexed citations

17.

Papadakis, Georgios Z., Corina Millo, Ulaş Bağcı, Jenny E. Blau, & Michael T. Collins. (2016). 18F-NaF and 18F-FDG PET/CT in Gorham-Stout Disease. Clinical Nuclear Medicine. 41(11). 884–885. 13 indexed citations

18.

Sylvetsky, Allison C., Viviana Bauman, Jenny E. Blau, et al.. (2015). Nonnutritive Sweeteners in Breast Milk. Journal of Toxicology and Environmental Health. 78(16). 1029–1032. 66 indexed citations

19.

Taylor, Simeon I., Jenny E. Blau, & Kristina I. Rother. (2015). SGLT2 Inhibitors May Predispose to Ketoacidosis. The Journal of Clinical Endocrinology & Metabolism. 100(8). 2849–2852. 396 indexed citations breakdown →

20.

Taylor, Simeon I., Jenny E. Blau, & Kristina I. Rother. (2014). Possible adverse effects of SGLT2 inhibitors on bone. The Lancet Diabetes & Endocrinology. 3(1). 8–10. 214 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact